Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 14, 2007

Chembio Issued Patent for Dual Path Immunoassay Device and Method

  • Chembio Diagnostics has been issued a U.S. patent for its "Dual Path Immunoassay Device." The patent describes a device and method for detection that includes a separate, second flow path for application of the sample material to be tested versus other solutions used in developing lateral flow rapid tests.

    This second flow path enables the development of diagnostic tests that can increase sensitivity, extends the spectrum of useful sample types beyond typical sources, such as blood, serum, and plasma, improves results when testing for multiple conditions and/or different parameters of one related condition, and reduces the amount of expensive reagents required, according to the company.

    While Chembio Diagnostics awaits additional patent protection in the U.S. and worldwide, it is seeking collaborations for this technology platform.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »